Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 25, 2010

Sinovac Wins $1.8M Chinese Flu Vaccine Contract and Gets Anflu Sanctioned in Hong Kong

  • Chinese vaccines firm Sinovac won a $1.8 million initial contract to supply the Chinese Centers for Disease Control and Prevention (Beijing CDC) with some 375,000 doses of its seasonal influenza vaccine Anflu®. The firm separately announced regulatory clearance of the vaccine by the Hong Kong Department of Health, and said it is evaluating marketing and distribution options for the Hong Kong market.

    The contract with the Beijing CDC means Sinovac will be the priority supplier of seasonal flu vaccine this year in China. Another four flu vaccine manufacturers have also won contracts for supplying the country with seasonal flu vaccines. The firm says the actual amount of vaccine supplied will depend on demand in Beijing.

    Sinovac’s marketed vaccines include Anflu, Healive (hepatitis A), Bilive (hepatitis A and B), Panflu (pandemic H5N1 flu), and Panflu.1 (Pandemic H1N1). Earlier this year Sinovac was selected by the Beijing CDC to supply its Healive vaccine to the Beijing Expanded Program of Immunization, which aims to broaden hepatitis A vaccination to encompass newborns by the end of 2010.

    Sinovac’s development pipeline includes vaccines against Enterovirus 71 (hand, foot, and mouth disease), a pneumococcal conjugate vaccine, Haemophilus influenza type B vaccine, and bacterial meningitis vaccine, along with candidates targeting Japanese encephalitis and severe acute respiratory syndrome.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »